-
Mashup Score: 1The Drug Development Letter | Vinay Prasad | Substack - 7 hour(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Special post-ESMO 2024 edition ! - 12 day(s) ago
Timothee Olivier and I discuss the top ESMO 2024 abstracts!
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
RT @Timothee_MD: @OncoAdvLukas @oncodaily @VPrasadMDMPH Here it is high-Q vid : https://t.co/CeaFPupyxd Enjoy !
-
-
Mashup Score: 1Artificial Intelligence in Medicine - My Keynote - 27 day(s) ago
Strengths and Limitations of AI in Healthcare
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Artificial Intelligence in Medicine: @VPrasadMDMPH 's Keynote. Strengths and Limitations of AI in Healthcare https://t.co/RymfZJPKZR
-
-
Mashup Score: 17Challenges with Reproducibility - 2 month(s) ago
My thoughts after a reproducibility paper was retracted.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Learn my take on this paper here: https://t.co/DJYDvwyDr3 https://t.co/FxOPzepHX6
-
-
Mashup Score: 19
A dive into the VISION trial, PSMAfore trial, and the questionable practices of the sponsor.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Devastating article about Lu-PSMA today in the drug development letter I see @FDAOncology is finally writing about the VISION trial in @JCO_ASCO I and others have been documenting that trials failures for years now. See this account https://t.co/MTJRDeaFrR
-
-
Mashup Score: 0The scattergun approach in research - a deep dive into CDK4/6 inhibitors tested in the neoadjuvant setting. - 2 month(s) ago
About forty trials enrolling thousands of patients have been launched since 2010.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
The scattergun approach in research: a deep dive into CDK4/6 inhibitors tested in the neoadjuvant setting. https://t.co/8JWROm8Bfb via #SaharBarjestehVanWaalwijkVanDoorn-Khosrovani https://t.co/Rla1yKIRBW
-
-
Mashup Score: 9An Educational Opportunity... ESMO2024 and the LEAP-012 trial! - 2 month(s) ago
How a colleague’s well-intended comments prompted me to explain several common misunderstandings that should be better taught during oncology training.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
How a colleague's well-intended comments prompted me to explain several common misunderstandings that should be better taught during oncology training. https://t.co/qR9Eo1xi5s via @VPrasadMDMPH
-
-
Mashup Score: 50Special ESMO 2024 edition ! - 2 month(s) ago
Timothee Olivier and I discuss the top ESMO 2024 abstracts!
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
Vitamin D trial was a waste of money 1 @Timothee_MD and I predicted this result in https://t.co/30bGA1Tz10 2 Drugs don't work in cancer without drug ACTIVITY aka response 3 we have meta analyzed this #ESMO24 https://t.co/LYNhdB6kPK https://t.co/thaxbBKlr2
-
-
Mashup Score: 1The Drug Development Letter | Vinay Prasad | Substack - 2 month(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
RT @pharmatinib: Check out our latest post on https://t.co/iCAC40k5ik @Timothee_MD @VPrasadMDMPH "While most discussions of the shortage c…
-
-
Mashup Score: 1The Drug Development Letter | Vinay Prasad | Substack - 3 month(s) ago
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases. Click to read The Drug Development Letter, by Vinay Prasad, a Substack publication with thousands of subscribers.
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet-
RT @pharmatinib: Check out our latest post on https://t.co/iCAC40k5ik @Timothee_MD @VPrasadMDMPH "While most discussions of the shortage c…
-
RT @pharmatinib: Check out our latest post on https://t.co/iCAC40k5ik @Timothee_MD @VPrasadMDMPH "While most discussions of the shortage c…